Skip to main content
Fig. 3 | Experimental Hematology & Oncology

Fig. 3

From: Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma

Fig. 3

Long-term outcome of patients. A. Duration time of remission after ASCT following CAR30 T-Cell infusion. The red column represents complete response (CR) and the blue column represents partial response (PR). Arrow indicates ongoing response. B, C. Propability of PFS (B) or OS (C) of enrolled patients after ASCT following CAR30 T-Cell infusion. Tick marks represent censored data. P patient

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us